fda compounding semaglutide crackdown news today The announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded (Wegovy) weight-loss pill from the UPDATE: FDA's Makary pledges crackdown

Track behavioral signals closely: Monitor attachment rates, combo mix, snack incidence, beverage mix, and protein-led item performance to understand how the shift is affecting your customer base

Successful weight reduction through these medications may actually decrease long-term thrombotic risk by addressing obesity as a modifiable risk factor

Rathi A et al

That is not a reason to ignore the signal it is a reason to qualify it

Unlike a hard tablet that sits on a shelf, a liquid peptide is sensitive to its environment

Matching accounted for demographics, body mass index (BMI), hemoglobin A1c, and multiple comorbidities